Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEB-001-Expanded Stem Cells for Poor Graft Function in Pediatric HSCT Patients
NCT07907172Phase 1Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label, single-arm trial of HEB-001 in poor graft function (PGF). Primary endpoints: Participants With Treatment-Related Acute Adverse Events at Day 30 and Participants With Evidence of Clonal Hematopoiesis or Driver Mutations at 1 year. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HEB-001
03
Conditions
poor graft function (PGF)
Beyond the preview
Go deeper on NCT07907172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907172.